HRTIS — Herantis Pharma Oyj Share Price
0.000.00%
Last trade - 00:00- €33.37m
- €33.42m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -259.36% | ||
| Return on Equity | -220.33% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Herantis Pharma Oyj is a Finland-based clinical stage biotech company with a diverse pipeline of investigational therapeutics looking to modify the course of debilitating nervous system and lymphatic diseases. Leveraging research about protein dysregulation for neurodegenerative diseases, and growth stimulation in lymphatic diseases, Herantis develops a pipeline of regenerative biological and gene therapies for high impact diseases. These include CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson’s disease and other neurodegenerative diseases, Lymfactin VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases. Herantis is pursuing disease modifying treatments that aims to slow, stop, or even reverse the course of diseases, and bring innovation to these diseases.
Directors
- Timo Veromaa NEC (62)
- Frans Wuite CEO
- Antti Vuolanto COO
- Henri Huttunen CSO
- Arnab Bhattacharjee OTH
- Sigrid Booms OTH
- Rebecka Holmnas OTH
- Katarina Jaaskelainen OTH
- Jani Koskinen OTH
- Natalia Kulesskaya OTH
- Outi Lahdenpera OTH
- Satu Leikas OTH
- Jutta Poutanen OTH
- Magnus Sjogren OTH (57)
- Paivi Vuorio OTH
- Hilde Furberg DRC (63)
- Aki Prihti DRC
- James Phillips IND (57)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 17th, 2008
- Public Since
- June 11th, 2014
- No. of Employees
- 11
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange - Helsinki
- Shares in Issue
- 24,094,817
- Address
- Bertel Jungin aukio 1, ESPOO, 02600
- Web
- https://herantis.com/
- Phone
- +358 92221195
- Contact
- Julie Silber
- Auditors
- PricewaterhouseCoopers Oy
Upcoming Events for HRTIS
Similar to HRTIS
Nanoform Finland Oyj
OMX Nordic Exchange - Helsinki
Nightingale Health Oyj
OMX Nordic Exchange - Helsinki
Solar Foods Oyj
OMX Nordic Exchange - Helsinki
FAQ
What is the Herantis Pharma Oyj share price?
As of Today at 21:05 UTC, shares in Herantis Pharma Oyj are trading at €1.39. This share price information is delayed by 15 minutes.
How has the Herantis Pharma Oyj share price performed this year?
Shares in Herantis Pharma Oyj last closed at €1.39 and the price had moved by -3.15% over the past 365 days. In terms of relative price strength the Herantis Pharma Oyj share price has underperformed the FTSE Global All Cap Index by -5.57% over the past year.
What are the analyst and broker recommendations for Herantis Pharma Oyj?
The overall consensus recommendation for Herantis Pharma Oyj is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Herantis Pharma Oyj dividend yield?
Herantis Pharma Oyj does not currently pay a dividend.
Does Herantis Pharma Oyj pay a dividend?
Herantis Pharma Oyj does not currently pay a dividend.
When does Herantis Pharma Oyj next pay dividends?
Herantis Pharma Oyj does not currently pay a dividend.
How do I buy Herantis Pharma Oyj shares?
To buy shares in Herantis Pharma Oyj you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Herantis Pharma Oyj?
As of the previous close price of €1.39, shares in Herantis Pharma Oyj had a market capitalisation of €33.37m.
Where are Herantis Pharma Oyj shares listed?
Here are the trading details for Herantis Pharma Oyj:
- Country of listing: Finland
- Exchange: HEX
- Ticker Symbol: HRTIS
What kind of share is Herantis Pharma Oyj?
Based on an overall assessment of its quality, value and momentum Herantis Pharma Oyj is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Herantis Pharma Oyj share price forecast for 2025?
The analyst consensus target price for shares in Herantis Pharma Oyj is €1.30. That is 6.14% below the last closing price of €1.39.
Analysts covering Herantis Pharma Oyj currently have a consensus Earnings Per Share (EPS) forecast of -€0.29 for the next financial year.
Find out moreWhat is the trend in the Herantis Pharma Oyj share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Herantis Pharma Oyj. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -2.93%.
As of the last closing price of €1.39, shares in Herantis Pharma Oyj were trading -5.24% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Herantis Pharma Oyj PE Ratio?
The Herantis Pharma Oyj PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €1.39.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Herantis Pharma Oyj?
Herantis Pharma Oyj's management team is headed by:
- Timo Veromaa - NEC
- Frans Wuite - CEO
- Antti Vuolanto - COO
- Henri Huttunen - CSO
- Arnab Bhattacharjee - OTH
- Sigrid Booms - OTH
- Rebecka Holmnas - OTH
- Katarina Jaaskelainen - OTH
- Jani Koskinen - OTH
- Natalia Kulesskaya - OTH
- Outi Lahdenpera - OTH
- Satu Leikas - OTH
- Jutta Poutanen - OTH
- Magnus Sjogren - OTH
- Paivi Vuorio - OTH
- Hilde Furberg - DRC
- Aki Prihti - DRC
- James Phillips - IND